Aldeyra Therapeutics Inc., a biotech firm based in Lexington, Massachusetts, has been working tirelessly to develop and commercialize medicines aimed at treating immune-mediated diseases. One of its top products currently under development is reproxalap, a reactive aldehyde species (RASP) modulator that is in Phase III clinical trial for use in treating dry eye diseases. Additionally, the company has also been exploring other RASP modulators, including ADX-629, an orally administered product with the potential to treat COVID-19, atopic asthma, psoriasis, and even alcohol intoxication. Aldeyra Therapeutics Inc. is also working on ADX-2191, a dihydrofolate reductase inhibitor that could have applications in the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, among other rare retinal diseases characterized by inflammation and vision loss. Looking ahead, the company is working on several other drugs: ADX-246 for systemic immune-mediated disease and ADX-248 for geographic atrophy. Aldeyra Therapeutics Inc. was founded in 2004 and previously operated as Aldexa Therapeutics Inc. before changing its name in March 2014.
Aldeyra Therapeutics Inc's ticker is ALDX
The company's shares trade on the NASDAQ stock exchange
They are based in Lexington, Massacusetts
There are 1-10 employees working at Aldeyra Therapeutics Inc
It is aldeyra.com
Aldeyra Therapeutics Inc is in the Healthcare sector
Aldeyra Therapeutics Inc is in the Biotechnology industry
The following five companies are Aldeyra Therapeutics Inc's industry peers: